Cigna Group $CI Stock Holdings Lessened by Seizert Capital Partners LLC

Seizert Capital Partners LLC cut its holdings in Cigna Group (NYSE:CI) by 0.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 150,491 shares of the health services provider’s stock after selling 480 shares during the period. Cigna Group comprises approximately 2.2% of Seizert Capital Partners LLC’s holdings, making the stock its 15th biggest position. Seizert Capital Partners LLC’s holdings in Cigna Group were worth $49,749,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Valeo Financial Advisors LLC raised its position in shares of Cigna Group by 86,071.1% during the 2nd quarter. Valeo Financial Advisors LLC now owns 3,475,282 shares of the health services provider’s stock worth $1,148,859,000 after purchasing an additional 3,471,249 shares during the period. Nuveen LLC acquired a new position in shares of Cigna Group during the first quarter valued at $727,905,000. Price T Rowe Associates Inc. MD grew its position in shares of Cigna Group by 10.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,056,806 shares of the health services provider’s stock worth $3,966,690,000 after acquiring an additional 1,094,327 shares during the last quarter. GQG Partners LLC increased its holdings in shares of Cigna Group by 21.5% in the 1st quarter. GQG Partners LLC now owns 4,886,674 shares of the health services provider’s stock worth $1,607,716,000 after acquiring an additional 865,092 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Cigna Group by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,649,837 shares of the health services provider’s stock valued at $542,796,000 after purchasing an additional 457,052 shares during the last quarter. Institutional investors and hedge funds own 86.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on CI shares. Morgan Stanley restated an “overweight” rating and issued a $355.00 price target on shares of Cigna Group in a research note on Friday, October 31st. Jefferies Financial Group reaffirmed a “buy” rating and set a $310.00 target price on shares of Cigna Group in a research note on Monday, November 3rd. Wolfe Research reduced their price target on Cigna Group from $345.00 to $325.00 and set an “outperform” rating for the company in a research report on Wednesday, October 15th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Cigna Group from $415.00 to $301.00 and set a “buy” rating on the stock in a research note on Monday, November 3rd. Finally, Barclays decreased their price target on Cigna Group from $383.00 to $300.00 and set an “overweight” rating for the company in a research note on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cigna Group has a consensus rating of “Moderate Buy” and a consensus price target of $334.05.

Cigna Group Stock Up 0.4%

Shares of Cigna Group stock opened at $272.50 on Wednesday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 0.65. Cigna Group has a 12-month low of $239.51 and a 12-month high of $350.00. The firm has a market capitalization of $72.79 billion, a PE ratio of 14.87, a price-to-earnings-growth ratio of 0.88 and a beta of 0.44. The stock’s fifty day moving average is $288.56 and its 200-day moving average is $299.97.

Cigna Group (NYSE:CI) last announced its earnings results on Thursday, October 30th. The health services provider reported $7.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.64 by $0.19. The company had revenue of $69.57 billion for the quarter, compared to the consensus estimate of $66.40 billion. Cigna Group had a net margin of 1.92% and a return on equity of 18.80%. The company’s revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the business earned $7.51 EPS. Cigna Group has set its FY 2025 guidance at 29.600- EPS. Equities analysts anticipate that Cigna Group will post 29.77 earnings per share for the current year.

Cigna Group Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Thursday, December 4th will be given a dividend of $1.51 per share. The ex-dividend date of this dividend is Thursday, December 4th. This represents a $6.04 dividend on an annualized basis and a yield of 2.2%. Cigna Group’s payout ratio is presently 26.64%.

Insider Activity at Cigna Group

In related news, CEO David Cordani bought 4,134 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was bought at an average price of $241.88 per share, for a total transaction of $999,931.92. Following the transaction, the chief executive officer directly owned 157,935 shares in the company, valued at $38,201,317.80. This represents a 2.69% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian C. Evanko sold 5,368 shares of the business’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $300.00, for a total transaction of $1,610,400.00. Following the transaction, the insider owned 51,182 shares in the company, valued at approximately $15,354,600. This represents a 9.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.70% of the stock is currently owned by corporate insiders.

Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.